

Noriko Satake, M.D.

Clinical Interests Dr. Satake's research focuses on the development of targeted therapies for pediatric cancers, with a special emphasis on leukemia and neuroblastoma. She is currently developing targeted therapies using nanoparticles, chemotherapeutic drugs, and siRNA, with leukemia-specific ligands and antibodies.

She has developed a human leukemia xenograft mouse model and used this model to evaluate markers for leukemia stem cells. Through a collaboration she initiated with a local company, she has also developed a mouse model of a rare pediatric cancer, which will be used to study this cancer and evaluate new therapies.

Her other research focus is translation of bioengineering technologies into clinical applications. She has established strong collaborations with bioengineers at the UC Davis Center for Biophotonics Science and Technology, particularly in the application of Raman spectroscopy in the clinic. In a previous collaboration, she studied leukemia cells in cerebrospinal fluid using Raman spectroscopy as an objective measurement of central nervous system leukemia. More recently, they have begun to focus on red blood cells.

Title Associate Professor

Specialty [Cancer](#), Pediatric Hematology/Oncology

Department [Pediatrics](#)

Division Pediatric Hematology/Oncology


Center/Program Affiliation [Stem Cell Research Program](#)
[Stem Cell Transplant Program](#)
[UC Davis Children's Hospital](#)
[UC Davis Comprehensive Cancer Center](#)

Address/Phone Ticon II Building, 2516 Stockton Blvd. Sacramento, CA 95817
Phone: 916-734-5177

Languages Japanese

Education M.D., Asahikawa Medical College, 1990

Residency



Noriko Satake, M.D.

Fellowships

Children's Medical Center, Wright State University, Dayton, Ohio, 2003
Hokkaido University School of Medicine, Sapporo, 1994
Children's Hospital Los Angeles, Los Angeles, California, 1998
Children's Hospital Los Angeles, Los Angeles, California, 2001
UCLA, Los Angeles, California, 2006

Board Certifications

American Board of Pediatrics, 2004
American Board of Pediatrics, Pediatric Hematology-Oncology, 2006

Select Recent Publications

Thampi S, Salmi D, Imashuku S, Ducore J, Satake N. Thrombotic thrombocytopenic purpura in a child with systemic lupus erythematosus. *Pediatr Hematol Oncol.* 2011 Apr;33(3):221-3.

Marsh RA, Satake N, Biroshchak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. *Pediatr Blood Cancer.* 2010 Jul 15;55(1):134-40.

Salmi D, Bhat A, Corman L, Raff G, Satake N. Diagnostic challenges in native valve fungal endocarditis producing a massive septic pulmonary embolus. *Nihon Ishinkin Gakkai Zasshi.* 2010; 51(4):207-10.

Salmi D, Patel C, Imashuku S, Shimada H, Satake N. Neuroblastoma of unknown primary site with periorbital bone metastasis in a child. *Pediatr Blood Cancer.* 2010 Aug;55(2):361-3.

Satake N., Yoon J. Acute Lymphoblastic Leukemia. *e-Medicine.* 2009

Zheng Y., Rozengurt N., Ryazantsev S., Kohn D.B., Satake N., Neufeld E. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. *Molecular Genetics and Metabolism,* 79(4): 233-244. 2003

Skelton D., Satake N., Kohn D.B. The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. *Gene Ther,* 8(23): 1813-1814. 2001

Anderson C.P., Seeger R.C., Satake N., Monforte-Munoz H.L., Keshelava N., Bailey H.H., Reynolds C.P. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphanlan-resistant neuroblastoma cell line. *J Pediatr. Hematol. Oncol.,* 23: 500-505. 2001

Anderson C.P., Keshelava N., Satake N., Meek W.H., Reynolds C.P. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. *Med. Pediatr. Oncol.,* 35: 659-662. 2000

Inaba H., Kawasaki H., Nakamura S., Yamamoto H., Kaneko Y., Satake N., Komada Y., Ito M., Sakurai M. Anaplastic large cell lymphoma associated with Sjogrens syndrome. *Leuk. Lymphoma,* 32: 183-188. 1998

© 2019 UC Regents